Bolt Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bolt Biotherapeutics, Inc. on April 15, 2025. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol "BOLT". The report addresses a corporate governance amendment effective immediately as of the filing date.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a change to the Company's bylaws and does not contain financial statements or operational metrics.
Material Changes
The Board of Directors amended and restated the Company's Bylaws to modify the quorum requirements for stockholder meetings:
- General Quorum: Reduced from a majority of outstanding shares to one-third (1/3) of outstanding shares entitled to vote.
- Class Vote Quorum: Reduced from a majority of outstanding shares of the specific class to one-third (1/3) of outstanding shares of that class present or represented by proxy.
- Method of Attendance: Quorum may be established by presence in person, by remote communication, or by proxy.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, risks, contingencies, or unusual items. The document is strictly procedural regarding the amendment of corporate bylaws.
Key Facts for Investor Verification
- Verify the full text of the Amended and Restated Bylaws filed as Exhibit 3.1 to understand the complete scope of the governance changes.
- Confirm the impact of the reduced quorum threshold (from majority to one-third) on the Company's ability to conduct business at future stockholder meetings.
- Note that this filing does not disclose any financial performance data or operational updates for the period.